Ownership and insider activity for AEON Biopharma, Inc. (AEON): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
AEON Biopharma, Inc. is a biopharmaceutical company primarily engaged in developing therapies based on botulinum toxins, aimed at treating various debilitating medical conditions. Among its key investigational products is ABP-450, a 900 kDa botulinum toxin complex, which is being advanced for therapeutic use in conditions such as migraine, cervical dystonia, and gastroparesis. The entity, originally known as ALPHAEON Corporation, adopted the name AEON Biopharma, Inc.
Price
| Price | $0.26 |
| Market Cap | $11M |
| Exchange | AMEX |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-08-19 | LYNCH TIMOTHY P | P-Purchase | 1,150,000 | $243K |
| 2026-08-19 | LYNCH TIMOTHY P | |||
| 2026-08-19 | LYNCH TIMOTHY P | 1,000,000 | $100 | |
| 2026-07-15 | LYNCH TIMOTHY P | 3,000,000 | $966K | |
| 2026-07-15 | LYNCH TIMOTHY P | 3,000,000 | $1.1M | |
| 2026-06-17 | Thunen Shelley B | A-Award | 222,684 | |
| 2026-06-17 | PALMISANO ROBERT J | A-Award | 222,684 | |
| 2026-06-17 | Forth Marc | A-Award | 222,684 | |
| 2026-06-17 | FISCHER JOST | A-Award | 222,684 | |
| 2026-06-17 | Carter Eric G | A-Award | 222,684 |
Balance Sheet (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $6.3M | $20.2M | $5.1M | $9.7M | $5.2M | $13000 | $3.0M |
| Short-term Investments | $105.4M | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | $267000 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $112.1M | $20.4M | $5.2M | $9.8M | $6.2M | $1.6M | $3.4M |
| Property, Plant & Equipment | 0 | 0 | $922000 | $906000 | $594000 | $1.5M | $1.2M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $114.4M | $21.2M | $6.4M | $10.8M | $6.8M | $3.1M | $5.6M |
| Accounts Payable | $1.0M | $2.0M | $1.2M | $7.8M | $3.4M | $5.9M | $942000 |
| Short-term Debt | $14.8M | 0 | $15.6M | $70.9M | 0 | 0 | 0 |
| Total Current Liabilities | $17.5M | $4.2M | $20.8M | $82.6M | $13.0M | $14.1M | $6.9M |
| Long-term Debt | $15.2M | $72.2M | $70.8M | $60.4M | 0 | $11.7M | $34.6M |
| Total Liabilities | $180.2M | $224.4M | $230.3M | $281.2M | $159.9M | $31.7M | $60.6M |
| Retained Earnings | -$333.7M | -$366.6M | -$422.3M | -$474.8M | -$473.6M | -$431.6M | -$470.8M |
| Total Equity | -$67.2M | -$208.3M | -$234.9M | -$287.5M | -$153.0M | -$28.6M | -$55.0M |
| Total Debt | $30.0M | $72.2M | $86.9M | $131.5M | $278000 | $13.0M | $35.7M |
| Net Debt | -$81.8M | $52.0M | $81.8M | $121.8M | -$4.9M | $12.9M | $32.7M |
| Working Capital | $94.7M | $16.2M | -$15.7M | -$72.7M | -$6.8M | -$12.6M | -$3.5M |
Financial Health
| Debt / Equity | -0.18 |
| Current Ratio | 0.54 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -126.80 |
Profitability
| Return on Equity | 204.18% |
| Return on Invested Capital | 1699.74% |
| Return on Assets | -924.25% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ABP · APM · BOLT · CING · CLNN · CLRB · LYRA
Explore sector: Healthcare · Biotechnology
More sections of AEON: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks